Use of High Flow Nasal Cannula alone
OtherUse of high flow nasal cannula oxygen therapy alone
NCT Number: NCT04725084
Acute Respiratory Distress Syndrome (ARDS) is the main clinical presentation of SARS-CoV-2 (Covid-19) infected patients admitted in Intensive Care Unit (ICU).
During the first phase of the outbreak (between February and May 2020), the use of invasive Mechanical Ventilation (MV) was largely required with 63% of ICU patients intubated in the first 24 hours after admission and up to 80% of patients during the overall ICU stay. Mortality was especially higher when using MV in the first 24 hours. In contrast, the use of non-invasive oxygenation strategies in the first 24 hours was only 19% for High Flow Nasal Cannula oxygen therapy (HFNC) and 6% for Non-Invasive Ventilation (NIV).
Several non-invasive oxygenation strategies were proposed in order to delay or avoid MV in ICU patients suffering from Covid-19 ARDS. The use of HFNC became the recommended oxygenation strategy, based in particular on publications prior to the outbreak. The use of NIV or Continuous Positive Airway Pressure (CPAP) combined with HFNC have also been proposed. Although these non-invasive oxygenation strategies seem widely used in the second phase of the outbreak, they have not yet confirmed their clinical impact on MV requirement and patient's outcome. Moreover, no comparison has been made between these different non-invasive oxygenation strategies.
The aim of this study is to compare different non-invasive oxygenation strategies (HFNC, NIV, CPAP) on MV requirement and outcome in ICU patients treated for ARDS related to Covid-19.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Centre Hospitalier de Bethune, Béthune, Hauts-de-France, France
Retrospective multicenter observational registry in French intensive care unit including all consecutive patients admitted for acute respiratory distress syndrome related to SARS-CoV-2 pneumonia between1st July and 31th December 2020.
Patients characteristics, ICU treatments and outcome will be recorded.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Use of high flow nasal cannula oxygen therapy alone
Use of non-invasive ventilation combined or not with high flow nasal cannula oxygen therapy
Use of continuous positive airway pressure combined or not with high flow nasal cannula oxygen therapy
Time frame: Through Intensive Care Unit stay, an average of 15 days
Rate of refractory hypoxemia outcome defined by invasive Mechanical Ventilation (endotracheal intubation) requirement or death of non-intubated patients because of therapeutical limitation
Time frame: Through Intensive Care Unit stay, up to 1 month
Numbers of days without invasive mechanical ventilation during ICU stay and until ICU discharge
Time frame: At the moment of Intensive care unit discharge, up to 1 month
Rate of patients alive at the moment of intensive care unit discharge
Time frame: At the moment of Intensive care unit discharge, up to 1 month
Number of days spent in Intensive care unit
Time frame: Through Intensive Care Unit stay, up to 1 month
Number of complications during intensive care unit stay: pneumothorax, pneumomediastinum
Time frame: Through Intensive Care Unit stay, up to 1 month
Period of time (in hours or days) between admission in Intensive Care Unit and intubation requirement with invasive mechanical ventilation.
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Other
Comparison of Non-invasive Oxygenation Strategies in ICU Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome
Acronym: SONIC-19
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04588363
COVID-19, Coronaviridae Infections
Loma Linda, California, United States
View Trial DetailsNCT04933929
COVID-19, Coronaviridae Infections
Paris, IIe-de-France, France
View Trial DetailsNCT05249816
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Abu Dhabi, United Arab Emirates
View Trial DetailsNCT04851821
PHYTOTHERAPIE, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Sahloul, Sousse Governorate, Tunisia
View Trial Details